Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET

Company Participants

Gary Gillheeney - President and Chief Executive Officer

David Francisco - Chief Financial Officer

Conference Call Participants

Danielle Antalffy - SVB Leerink LLC

Steven Lichtman - Oppenheimer & Co.

Ryan Zimmerman - BTIG, LLC

Matthew Miksic - Credit Suisse AG

Operator

Good afternoon, ladies and gentlemen, and welcome to the First Quarter 2022 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the Company’s website for replay shortly.

Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A risk factors of the Company’s most recent annual report.

You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time-to-time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures and the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.

I would now like to turn the call over to Mr. Gary S. Gillheeney, Sr., Organogenesis Holdings President and Chief Executive Officer. Please go ahead, sir.

Gary Gillheeney

Thank you, operator, and welcome everyone to Organogenesis Holdings first quarter 2022 earnings conference call. I am joined on the call today by Dave Francisco, our Chief Financial Officer.

Let me start with a brief agenda of what we will cover during our prepared remarks. I'll start with a high level review of our first quarter revenue results. I'll then provide a review of some of the recent operating highlights. And after my opening remarks, Dave will provide you with a more in-depth review of our first quarter financial results, our balance sheet and financial condition at the end of the first quarter and the guidance for 2022 that we reaffirmed in today's press release. Then we'll open up the floor for questions.